CREO
NEUTRALCreo Medical Announces Capital Markets Day
The medical device company Creo Medical Group announces plans to host a Capital Markets Day for investors and analysts.
Creo Medical Group
11.25GBX
0.00%
Market Cap
46.40M
Volume
21.05k
3% of avg
P/E Ratio
-3.81
EPS (TTM)
-2.95
Beta
0.55
Day Range
11.00p - 11.50p
52 Week Range
9.22p11.25p22.50p
11.25p
Upcoming Events
19 November 2025
Capital Markets Day
May 2026
Expected release of FY2025 financial results
High Impact Event
CREO
NEUTRALCreo Medical Reschedules Capital Markets Day
The medical device company has announced it will reschedule its upcoming Capital Markets Day event due to a scheduling conflict with a keynote speaker.
CREO
NEUTRALCreo Medical Reports 40% Revenue Growth in H1 2025, Reduces Operating Losses
The medical device company reported 40% revenue growth and reduced operating losses by 43%, while expanding its product portfolio and clinical adoption. However, it remains unprofitable with ongoing cash burn.
CREO
NEUTRALCreo Medical Group Announces Holding Change
The healthcare company has announced a change in its major shareholding, with M&G Plc increasing its stake to over 12%.
CREO
NEUTRALCreo Medical Announces Interim Results Presentation
The medical device company will announce its interim results and host an online investor presentation.
CREO
NEUTRALCreo Medical Group CFO Transfers Shares to Children
The medical device company's CFO has transferred a portion of his shareholding to his children.
CREO
NEUTRALCreo Medical highlights successful Speedboat® procedure for patient
The medical device company shares a patient testimonial highlighting the benefits of its Speedboat® technology, which helped a patient avoid major surgery.
CREO
NEUTRALCreo Medical Group Awards Shares Under SIP, Directors Increase Stake
The medical device company has awarded shares to employees and directors under its Share Incentive Plan.
CREO
GOODCreo Medical Reports 40% Core Technology Revenue Growth in H1'25
The medical device company reports 40% growth in core technology revenues in the first half of 2025, in line with expectations, and is tracking on plan for full-year guidance.
CREO
NEUTRALCreo Medical Begins Landmark Lung Tumour Clinical Study for MicroBlate™ Flex
The medical device company has commenced a new clinical study evaluating the safety and performance of its MicroBlate™ Flex device for treating lung tumours.